Astellas to Acquire AMEVIVE® (alefacept)
Acquisition of psoriasis product deepens Astellas' Commitment to Dermatology franchise
05-Apr-2006 -
Astellas Pharma US, Inc. and Biogen Idec Inc. announced that an agreement for Astellas to purchase the worldwide rights to AMEVIVE® (alefacept) was executed as of March 31, 2006. AMEVIVE is a biologic anti-inflammatory compound used in the treatment of moderate-to-severe plaque psoriasis.
Under ...
Astellas Pharma
Biogen Idec
clinical trials
+1